Yasuda H, Tomita T, Fujita K, Shibata J, Tateda K, Yokota H, Igarashi T, Ogasawara S, Yamazaki M, Oyama Y
Arzneimittelforschung. 1984;34(5):614-9.
Some Ca2+-antagonists are used for the treatment of angina pectoris. In the present study niludipine (Bay a 7168) was assessed in various types of angina pectoris cases. Niludipine, a Ca2+-antagonist of the dihydropyridine derivatives, was administered to 50 patients, 27 with effort angina pectoris, 4 with rest angina, 7 with effort plus rest angina, 4 with variant angina, 8 with angina following myocardial infarction in the doses of 60 mg/day or 120 mg/day for 4 weeks and the changes of subjective symptoms and objective findings were evaluated. Improvement was found by 69.6% for effort angina, by 75% (3/4) for rest angina, and side effects by 6% but mild degree--no facial flash, headache, hypotension were observed. The results suggest that niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris.
一些钙拮抗剂用于治疗心绞痛。在本研究中，对尼鲁地平（Bay a 7168）在各类心绞痛病例中的疗效进行了评估。尼鲁地平是一种二氢吡啶衍生物类钙拮抗剂，对50例患者进行了给药治疗，其中27例为劳力性心绞痛患者，4例为静息性心绞痛患者，7例为劳力合并静息性心绞痛患者，4例为变异性心绞痛患者，8例为心肌梗死后心绞痛患者，剂量为每日60毫克或120毫克，疗程4周，并对主观症状和客观检查结果的变化进行了评估。劳力性心绞痛的改善率为69.6%，静息性心绞痛的改善率为75%（3/4），副作用发生率为6%，但程度较轻，未观察到面部潮红、头痛、低血压等症状。结果表明，尼鲁地平是一种安全的抗心绞痛钙拮抗剂，对各类心绞痛均有广泛疗效。
